Results and discussion
In a search for cell-surface proteins with a functional link to CD82/KAI-1, we found that anti-CD82 monoclonal antibodies could co-immunoprecipitate EGFR from three different types of epithelial cells: small-cell lung carcinoma (A549), primary keratinocytes and human mammary epithelial cells (HB2/CD82) ( Figure 1a ). In the reciprocal experiment using HB2/CD82 cells, we detected CD82/KAI-1 in the EGFR immunoprecipitates as a characteristic smearing 33-38 kDa doublet (Figure 1b) . The a3b1 integrin, a principal integrin partner of CD82/KAI-1 in epithelial cells [9] , was not found in the anti-EGFR immunoprecipitate prepared from HB2/CD82 cells (Figure 1c) , implying that the CD82-EGFR and CD82-α3β1 complexes exist as separate entities on the cell surface. Densitometric measurements indicated that approximately 15-20% of the total EGFR in HB2/CD82 cells could be co-immunoprecipitated with CD82/KAI-1.
To establish the functional significance of the CD82-EGFR association, we compared EGF-induced responses in a newly developed pair of cell lines, HB2/zeo and HB2/CD82. Derived from the HB2 cells, both lines were selected as combined pools of drug-resistant colonies to account for clonal variability. As assessed by flow cytometry, HB2/CD82 cells expressed CD82/KAI-1 at levels > 25-fold those in HB2/zeo cells. When motility responses were analyzed in the wound closure assay, we found that EGF-dependent migration of HB2/CD82 cells over 8 hours was decreased by more than 30% compared with HB2/zeo cells (Figure 2a) . In contrast, migration in response to fetal calf serum (FCS) was similar for both lines (Figure 2a ). Using time-lapse video microscopy, we found that early morphological responses to EGF were also different. During the first 10 minutes after the EGF Internalization and intracellular trafficking of the stimulated EGF receptor are important for diversifying the intracellular signals [11] . Dissociation of the endocytosed EGF-EGFR complex in late endosomes and lysosomes leads to desensitization of the receptor and attenuation of EGF-induced signaling. (Figure 4a ). Second, we examined the removal of EGFR from the cell surface after cells were treated with a saturated concentration of EGF. In the HB2/CD82 cells, only 30% of the EGFR remained on the surface after treatment with EGF for 5 minutes, whereas more than 80% was still present on (Figure 4b) . The difference was even more dramatic after 60 minutes: ~50% of the initial amount of EGFR was detected on the surface of HB2/zeo cells compared with 8% on HB2/CD82 cells. In controls, we found that biotinylated EGFR disappeared from the surface of untreated cells at a comparable slow rate in both cell lines (data not shown). These results show that expression of CD82/KAI-1 in epithelial cells accelerated ligand-induced clearance of EGFR from the cell surface. As the levels of EGFR in HB2/zeo and HB2/CD82 cells exceed those of other members of the ErbB family (E.O., unpublished results), the majority of the internalized receptors are destined for lysosomal degradation and inactivation of the receptor's signaling capacity. Consequently, the enhanced rate of endocytosis can account for the rapid attenuation of EGF-induced signaling in the HB2/CD82 cells.
The EGF family of polypeptides are crucial to various normal and pathological processes, including tissue differentiation, wound healing and tumorigenesis. EGF-induced signaling is controlled at various levels. These include the ligand-induced dimerization of EGFR [12] [13] [14] , membrane compartmentalization of the activated receptor and its substrates [15] [16] [17] and the intracellular routing of the receptor and its degradation [18, 19] . Although the molecular mechanisms of these processes are not fully understood, they are each thought to involve distinct interactions between ErbB receptors and other cellular proteins. Our results identify CD82/KAI-1 tetraspanin as a new attenuator of EGF-induced signaling, facilitating ligand-induced endocytosis of the receptor and its subsequent desensitization. Consequently, the migratory response to EGF was dramatically attenuated in cells expressing CD82/KAI-1. These data provide further support for the idea that ligand-induced endocytosis of surface receptors is an integral part of the signaling process that controls the amplitude of cellular responses [20] .
CD82/KAI-1 is associated with the EGFR membrane complex, thus providing a first example of an accessory transmembrane protein that regulates clearance of the ligand-bound receptor from the cell surface. Interestingly, Brief Communication 1011 the EGFR-CD82 complex is destabilized when EGF binds to the receptor (see Supplementary material). This observation not only distinguishes the EGFR-CD82 complex from other associations involving EGFR, but also suggests that the tetraspanin may predetermine the signaling potency of the receptor before its activation.
Other members of the tetraspanin superfamily can form complexes with a variety of surface transmembrane receptors including integrins, CD4, CD8, CD19 and MHC class II molecules [7, 8] , and it has been hypothesized that tetraspanins modulate the receptors' signaling activity [7, 8, 21] . Our results show that tetraspanins may be involved in the regulation of a particular step of the signaling process, such as endocytosis of the activated receptor. This is an important clue towards understanding the role of the tetraspanins in signaling initiated by other receptors.
EGFR and CD82/KAI-1 are expressed together in a variety of normal epithelia. Our results strongly suggest that a change in the relative expression of these proteins in epithelial tumors (for example, downregulation of CD82/KAI-1 [2] [3] [4] [5] [6] or overexpression of EGFR) would affect an important suppressive control on EGF-induced signaling. The consequent sustained activation of EGFR and protracted generation of proliferative and migratory signals could enable the spread of the tumor and progression of the disease.
Supplementary material
Supplementary material including additional methodological details and figures showing the effects of EGF on the EGFR-CD82 complex and the effects of CD82/KAI-1 on EGFR compartmentalization is available at http://current-biology.com/supmat/supmatin.htm.
